Press Releases Chimerix, Inc.

Equities

CMRX

US16934W1062

Real-time Estimate Cboe BZX Other stock markets 03:23:49 2024-04-29 pm EDT			5-day change	1st Jan Change
0.925 ^USD	+2.79%		+0.81%	-4.28%

Mar. 21	Chimerix Appoints Marc D. Kozin to Board of Directors	CI
Feb. 29	Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024	Apr. 24	AQ
Chimerix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Apr. 17	AQ
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 16	AQ
Chimerix Appoints Marc D. Kozin to Board of Directors	Mar. 21	AQ
Chimerix: Q4 Earnings Snapshot	Feb. 29	AQ
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update	Feb. 29	AQ
Chimerix to Present at TD Cowen 44th Annual Health Care Conference	Feb. 27	AQ
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024	Feb. 22	AQ
Chimerix Appoints Lisa Decker to Board of Directors	Dec. 29	AQ
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer	Dec. 04	AQ
Chimerix Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Nov. 27	AQ
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Nov. 24	AQ
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer	Nov. 16	AQ
Chimerix : Corporate Presentation	Nov. 02	PU
Chimerix: Q3 Earnings Snapshot	Nov. 02	AQ
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update	Nov. 02	AQ
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023	23-10-26	AQ
Chimerix : Corporate Presentation	23-09-12	PU
Chimerix to Participate in Upcoming Investor Conferences	23-09-05	AQ
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"	23-08-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Chimerix, Inc.

Equities

CMRX

US16934W1062

Press Releases

Filters